First test of new genetic therapy for rare lung disease
NCT ID NCT06677307
Summary
This is the first human study of an experimental drug called KRRO 110 for Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause lung and liver disease. The trial will test single and multiple doses in 64 healthy volunteers and people with AATD to check safety, how the body processes the drug, and its effect on key protein levels. The main goal is to see if the treatment is safe and well-tolerated before further testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AATD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Zealand Clinical Research
Auckland, New Zealand
-
New Zealand Clinical Research
Christchurch, New Zealand
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
-
St. Vincent's Hospital Melbourne
Melbourne, Victoria, 3065, Australia
-
The Prince Charles Hospital
Brisbane, Queensland, 4032, Australia
Conditions
Explore the condition pages connected to this study.